E-mail a Wiley Online Library Link

K. T. Smerud, S. Dolgos, I. C. Olsen, A. Åsberg, S. Sagedal, A. V. Reisæter, K. Midtvedt, P. Pfeffer, T. Ueland, K. Godang, J. Bollerslev and A. Hartmann A 1-Year Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Ibandronate on Bone Loss Following Renal Transplantation American Journal of Transplantation 12

Version of Record online: 4 SEP 2012 | DOI: 10.1111/j.1600-6143.2012.04233.x

This prospective, randomized, double-blind, placebo-controlled clinical trial of ibandronate as add-on to calcium and calcitriol in renal transplant recipients with early stable renal function shows that calcium and calcitriol supplementation maintain bone mineral density over 12 months, whereas ibandronate adds a significantly although modest protective effect against bone loss.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field